Compare DUO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | NVNO |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.3M |
| IPO Year | 2019 | N/A |
| Metric | DUO | NVNO |
|---|---|---|
| Price | $1.59 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 66.1K | ★ 539.5K |
| Earning Date | 03-13-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,189,313.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.30 | N/A |
| 52 Week Low | $1.24 | $0.30 |
| 52 Week High | $11.46 | $5.62 |
| Indicator | DUO | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 47.06 |
| Support Level | $1.54 | $0.33 |
| Resistance Level | $1.68 | $0.38 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 40.00 | 47.92 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.